We are live on ! Find out more
MGRX icon

Mangoceuticals
MGRX

8 hedge funds and large institutions have $72K invested in Mangoceuticals in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

106% more capital invested

Capital invested by funds: $34.9K → $72K (+$37.1K)

60% more funds holding

Funds holding: 5 → 8 (+3)

0.7% more ownership

Funds ownership: 0.73% → 1.43% (+0.7%)

Holders
8
Holders Change
+3
Holders Change %
+60%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Mercer Global Advisors
Mercer Global Advisors
Colorado
+$26.5K
2
Citadel Advisors
Citadel Advisors
Florida
+$24.4K
3
XT
XTX Topco
Cayman Islands
+$6.46K
4
MCG
McCollum Christoferson Group
New York
+$3.98K
5
UBS Group
UBS Group
Switzerland
+$3.83K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$8K
2
Vanguard Capital Wealth Advisors
Vanguard Capital Wealth Advisors
Colorado
-$6.92K

MGRX Hedge Fund Activity: Q1 2024 in Review

8 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q1 2024, worth a combined $72K — up 106% from $34.9K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new MGRX positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Mercer Global Advisors, opening a new position worth an estimated $26.5K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $8K sold.

  • 8 institutional investors held Mangoceuticals (MGRX) as of Q1 2024, up from 5 in Q4 2023.
  • Funds reported $72K of Mangoceuticals stock for Q1 2024, up 106% quarter-over-quarter.
  • 5 funds opened new Mangoceuticals positions in Q1 2024 and 2 closed out, a net change of +3 holders.
  • The largest Mangoceuticals buyer in Q1 2024 was Mercer Global Advisors, an estimated $26.5K added.
  • The largest Mangoceuticals seller in Q1 2024 was Renaissance Technologies, an estimated $8K sold.

Based on aggregated 13F filings for Q1 2024.